Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

6 terminated/withdrawn out of 12 trials

Success Rate

25.0%

-61.6% vs industry average

Late-Stage Pipeline

8%

1 trials in Phase 3/4

Results Transparency

250%

5 of 2 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

Phase 1
8(66.7%)
Phase 2
3(25.0%)
Phase 3
1(8.3%)
12Total
Phase 1(8)
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT07718243Phase 1Recruiting

Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC

Role: collaborator

NCT07672769Phase 2Not Yet Recruiting

Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

Role: lead

NCT05428969Phase 1Active Not Recruiting

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

Role: lead

NCT07460986Phase 1Not Yet Recruiting

A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA

Role: collaborator

NCT03733990Phase 1Completed

A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)

Role: lead

NCT05936229Phase 1Withdrawn

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Role: collaborator

NCT04860518Phase 2Terminated

Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19

Role: lead

NCT05171062Phase 1Withdrawn

Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer

Role: collaborator

NCT05104905Phase 1Withdrawn

A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma

Role: lead

NCT03119701Phase 2Terminated

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA

Role: lead

NCT02622724Phase 3Terminated

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)

Role: lead

NCT00789685Phase 1Completed

Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II

Role: lead

All 12 trials loaded